Unlock instant, AI-driven research and patent intelligence for your innovation.

Pharmaceutical composition containing trifluridine and tipiracil hydrochloride, and application thereof

A composition and drug technology, applied in the field of pharmaceutical preparations, can solve problems such as degradation

Inactive Publication Date: 2017-07-04
NANJING SANHOME PHARMACEUTICAL CO LTD
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

After oral administration, FTD is well absorbed but is easily degraded by hepatic thymidylate phosphorylase (TPase)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing trifluridine and tipiracil hydrochloride, and application thereof
  • Pharmaceutical composition containing trifluridine and tipiracil hydrochloride, and application thereof
  • Pharmaceutical composition containing trifluridine and tipiracil hydrochloride, and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Embodiment 1 Compatibility experiment of raw materials and auxiliary materials

[0043] The API (API) composed of FTD and TPI was mixed with microcrystalline cellulose 102 (MCC 102) and lactose (200mg:40mg) respectively, and the API was mixed with pregelatinized starch and micropowdered silica gel (SiO 2 ), stearic acid, magnesium stearate (MS), glyceryl behenate, talcum powder, polyethylene glycol 8000 (PEG 8000) according to (75mg: 75mg), mixed at high temperature and high humidity (40±2℃ / 75%±5%RH), light (4500±500lx), high temperature (60°C), high humidity (25°C / 92.5%RH) for 28 days, and inspected on the 0th, 7th, 14th and 28th day The change of total impurity content is shown in Table 1.

[0044] Table 1

[0045]

[0046]

[0047] The above experimental results show that the API (API) composed of FTD and TPI has poor compatibility stability with the commonly used diluent MCC102, and has poor compatibility with the commonly used lubricant micropowder silica ...

Embodiment 2-3

[0049] Weigh an appropriate amount of FTD and TPI, mix them at a molar ratio of 2:1, and grind them to particle size D 90 ≤100 μm, a mixed API is obtained. Mix lactose monohydrate (purchased from German Meiji Leversberg Dairy Co., Ltd.) and pregelatinized starch (from Shanghai Colorcon Coating Technology Co., Ltd.) in equal increments, and then add stearic acid (purchased from BASF Shanghai Co., Ltd.) and glyceryl behenate (purchased from Jiafashi Trading Co., Ltd.), mixed according to the prescription ratio shown in Table 2, and compressed into tablets.

[0050] Get some of the tablets prepared in Examples 2 and 3, place them under 40°C ± 2°C / 75% ± 5%RH (open) conditions for 28 days respectively, and investigate the total impurity content in 7 days, 14 days and 28 days Changes. The test results are shown in Table 3.

[0051] Table 2

[0052]

[0053] table 3

[0054]

[0055] The above results show that plain tablets prepared with stearic acid or glyceryl behenate ...

Embodiment 4

[0057] The plain tablet of embodiment 2 and 3 is coated with the HPC-SSL solution of about 7% solid content and the Opadry solution of about 7% respectively (the HPC-SSL solution preparation of about 7% solid content: weigh hydroxypropyl Add 24 g of cellulose-SSL (HPC-SSL) (purchased from Nippon Soda Co., Ltd.), add 318.86 g of absolute ethanol, and stir magnetically for 2 hours to obtain HPC-SSL solution; Opadry solution with a solid content of about 7% is prepared by weighing 54g of 295F680027 (purchased from Shanghai Colorcon Coating Technology Co., Ltd.), 720g of purified water was added, magnetically stirred for 2h, filtered through a 120-mesh sieve, and the filtrate was taken to obtain Opadry solution), to obtain the coated tablet of Example 2 and Example 3 coated tablets.

[0058] Take some of the coated tablets of Example 2 and Example 3 prepared in Example 4, and place them under the conditions of 40°C ± 2°C / 75% ± 5% RH (open) for 17 days respectively to investigat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention specifically relates to a pharmaceutical composition containing 2'-deoxy-5-(trifluoromethyl)uracil (FTD) and 5-chloro-6-[(2-aminopyrrolidin-1-yl)methyl]pyrimidyl-2,4-(1H,3H)-dione hydrochloride (TPI), more specifically to a pharmaceutical composition containing FTD, TPI, lactose, pregelatinized starch and glyceryl behenate, belonging to the field of medicinal preparations. The pharmaceutical composition and medicinal preparations provided by the invention are free of obvious increase in total impurity amount under the conditions of high temperature and high humidity and have good stability.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, in particular to a drug containing 2'-deoxy-5-(trifluoromethyl)uracil (FTD) and 5-chloro-6-[(2-aminopyrrolidin-1-yl)methanol Base] pyrimidine-2,4-(1H,3H)-dione hydrochloride (TPI) pharmaceutical composition, more specifically, the present invention relates to a kind of containing FTD, TPI, lactose, pregelatinized starch and bean Pharmaceutical composition of glyceryl ethanate. Background technique [0002] TAS-102 was developed by Dapeng Pharmaceutical Co., Ltd. of Japan. It consists of 1M 2'-deoxy-5-(trifluoromethyl)uracil (FTD, trifluridine) and 0.5M 5-chloro-6- A compound tablet composed of [(2-aminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione hydrochloride (TPI, tipirasole hydrochloride). FTD is the active ingredient of TAS-102's anti-tumor effect. It is a nucleoside analogue. Its monophosphate metabolite can be incorporated into DNA and exert its anti-tumor effect by inhib...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7072A61K31/513A61K47/36A61K47/38A61K9/20A61K9/28A61P35/00
CPCA61K9/2059A61K9/2866A61K31/513A61K31/7072A61K2300/00
Inventor 王勇陈良慧储刚束俭辉候振山
Owner NANJING SANHOME PHARMACEUTICAL CO LTD